AMENDMENTS TO THE CLAIMS:

Claims 2-16, 18-28 and 30-47 are pending in this application. Claims 1, 17 and 29 are cancelled herein without prejudice or disclaimer. Claims 2-6, 8-13, 18-22, 24-28, 30, 33-35, 41 and 43 are amended herein. New claims 44-47 are added herein. This listing of claims will replace all prior versions, and listings of claims, in the application.

LISTING OF CLAIMS:

1. (Cancelled).

2. (Currently amended) A compound according to ~~claim 1~~ any one of claims 44, 45 or 46, wherein R^1 is selected from the group of hydrogen, C_1–C_4 alkyl, COR^{11}, SO_2R^{11}, and $CONR^{11}R^{12}$.

3. (Currently amended) A compound according to ~~claim 1~~ any one of claims 44, 45 or 46, wherein R^2 and R^3 each independently is selected from the group of C_1–C_4 alkyl, and C_1–C_4 haloalkyl.

4. (Currently amended) A compound according to ~~claim 1~~ any one of claims 44, 45 or 46, wherein:

R^5 and R^7 taken together form a bond;

R^4 and R^6 each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR^{11}, C_1–C_4 alkyl, and C_1–C_4 haloalkyl.

5. (Currently amended) A compound according to ~~claim 1~~ any one of claims 44, 45 or 46, wherein:

R^6 and R^7 taken together are selected from the group of methylidene, and carbonyl;

R^4 and R^5 each independently is selected from the group of hydrogen, F, and C_1–C_4 alkyl.

6. (Currently amended) A compound according to ~~claim 1~~ any one of claims 44, 45 or 46, wherein R^8 through R^{10} each independently is selected from the group of hydrogen, F, Cl, Br, NO_2, CN, OR^{11}, SR^{11}, C_1–C_6 alkyl, C_1–C_6 heteroalkyl, and C_1–C_6 haloalkyl.

7. (Original) A compound according to claim 6, wherein R^8 through R^{10} each independently is selected from the group of hydrogen, F, and OR^{11}.

8. (Currently amended) A compound according to ~~claim 1~~ any one of claims 44, 45 or 46, wherein R^{11} through R^{12} each independently is selected from the group of hydrogen, and C_1–C_4 alkyl.

9. (Currently amended) A compound ~~according to claim 1, wherein~~ of the formula:



(I)

wherein:

R^1 is selected from the group of hydrogen, C_1–C_4 alkyl, C_1–C_4 haloalkyl, C_1–C_4 heteroalkyl, COR^{11}, CO_2R^{11}, SO_2R^{11}, and $CONR^{11}R^{12}$;

R^2 and R^3 each independently is selected from the group of hydrogen, C_1–C_6 alkyl, and C_1–C_6 haloalkyl; or

R^2 and R^3 taken together form a cycloalkyl ring of from three to twelve carbons;

R^4 through R^7 each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR^{11}, C_1–C_4 alkyl, C_1–C_4 haloalkyl, and C_1–C_4 heteroalkyl; or

R^5 and R^7 taken together form a bond; or

R^6 and R^7 taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene and carbonyl;

R^8 through R^{10} each independently is selected from the group of hydrogen, F, Cl, Br, I, NO_2, CN, OR^{11}, $NR^{11}R^{12}$, SR^{11}, COR^{11}, CO_2R^{11}, $CONR^{11}R^{12}$, C_1–C_8 alkyl, C_1–C_8 heteroalkyl, C_1–C_8 haloalkyl, allyl, C_2–C_8 alkenyl and C_2–C_8 alkynyl;

R^{11} and R^{12} each is independently selected from the group of hydrogen, C_1–C_4 alkyl, C_1–C_4 heteroalkyl, and C_1–C_4 haloalkyl;

R^{13} is hydrogen;

R^{14} and R^{16} taken together form a bond or "–O–" bridge;

R^{15}, R^{17}, R^{18}, R^{19}, R^{20} each independently is selected from the group of hydrogen, F, Cl, C_1–C_4 alkyl, and C_1–C_4 haloalkyl.

R^{21} is hydrogen; and

n is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt or prodrug thereof.

10. (Currently amended) A compound ~~according to claim 1, wherein~~ of the formula:



(I)

wherein:

R^1 is selected from the group of hydrogen, C_1–C_4 alkyl, C_1–C_4 haloalkyl, C_1–C_4 heteroalkyl, COR^{11}, CO_2R^{11}, SO_2R^{11}, and $CONR^{11}R^{12}$;

R^2 and R^3 each independently is selected from the group of hydrogen, C_1–C_6 alkyl, and C_1–C_6 haloalkyl; or

R^2 and R^3 taken together form a cycloalkyl ring of from three to twelve carbons;

R^4 through R^7 each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR^{11}, C_1–C_4 alkyl, C_1–C_4 haloalkyl, and C_1–C_4 heteroalkyl; or

R^5 and R^7 taken together form a bond; or

R^6 and R^7 taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene and carbonyl;

R^8 through R^{10} each independently is selected from the group of hydrogen, F, Cl, Br, I, NO_2, CN, OR^{11}, $NR^{11}R^{12}$, SR^{11}, COR^{11}, CO_2R^{11}, $CONR^{11}R^{12}$, C_1–C_8 alkyl, C_1–C_8 heteroalkyl, C_1–C_8 haloalkyl, allyl, C_2–C_8 alkenyl and C_2–C_8 alkynyl;

R^{11} and R^{12} each is independently selected from the group of hydrogen, C_1–C_4 alkyl, C_1–C_4 heteroalkyl, and C_1–C_4 haloalkyl;

R^{13} is hydrogen;

R^{14}, R^{15}, R^{18}, R^{19}, R^{20} each independently is selected from the group of hydrogen, F, Cl, C_1–C_4 alkyl, and C_1–C_4 haloalkyl.

R^{16} and R^{17} taken together are selected from the group of methylidene, mono-substituted methylidene, and di-substituted methylidene;

R^{21} is hydrogen; or

R^{21} and R^{20} taken together form a bond;

n is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt or prodrug thereof.

11. (Currently amended) A compound ~~according to claim 1, wherein~~ of the formula:



(I)

wherein:

R^1 is selected from the group of hydrogen, C_1–C_4 alkyl, C_1–C_4 haloalkyl, C_1–C_4 heteroalkyl, COR^{11}, CO_2R^{11}, SO_2R^{11}, and $CONR^{11}R^{12}$;

R^2 and R^3 each independently is selected from the group of hydrogen, C_1–C_6 alkyl, and C_1–C_6 haloalkyl; or

R^2 and R^3 taken together form a cycloalkyl ring of from three to twelve carbons;

R^4 through R^7 each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR^{11}, C_1–C_4 alkyl, C_1–C_4 haloalkyl, and C_1–C_4 heteroalkyl; or

R^5 and R^7 taken together form a bond; or

R^6 and R^7 taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene and carbonyl;

R^8 through R^{10} each independently is selected from the group of hydrogen, F, Cl, Br, I, NO_2, CN, OR^{11}, $NR^{11}R^{12}$, SR^{11}, COR^{11}, CO_2R^{11}, $CONR^{11}R^{12}$, C_1–C_8 alkyl, C_1–C_8 heteroalkyl, C_1–C_8 haloalkyl, allyl, C_2–C_8 alkenyl and C_2–C_8 alkynyl;

R^{11} and R^{12} each is independently selected from the group of hydrogen, C_1–C_4 alkyl, C_1–C_4 heteroalkyl, and C_1–C_4 haloalkyl;

R^{13} is hydrogen;

R^{14}, R^{15}, R^{17}, R^{20} each independently is selected from the group of hydrogen, F, Cl, C_1–C_4 alkyl, and C_1–C_4 haloalkyl R^{16} and R^{18} taken together form a bond when n is 1;

R^{16} and R^{19} taken together form a bond when n is 0;

R^{21} is hydrogen; and

n is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt or prodrug thereof.

12. (Currently amended) A compound ~~according to claim 1, wherein said compound is~~ selected from the group of:

(±)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **24**);

(±)-(*5l,1'u*)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **25**);

(+)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **27**);

(–)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **28**);

(±)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **29**);

(±)-(*5l,1'u*)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **30**);

(+)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **32**);

(–)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **33**);

(±)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **34**);

(±)-(*5l,1'u*)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **35**);

(+)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **37**);

(–)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **38**);

(±)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-9-methoxy-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **39**);

(±)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2-dimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **41**);

(±)-(*5l,1'u*)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2-dimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **42**);

(±)-(*5l,1'l*)-5-(3-methyl-2-cyclopentenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **44**);

(±)-(*5l,1'u*)-5-(3-methyl-2-cyclopentenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **45**);

(±)-(*5l,1'l*)-5-(3,5,5-trimethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **47**);

(±)-(*5l,1'u*)-5-(3,5,5-trimethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **48**);

(±)-(*5l,1'l*)-5-(3-methyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **50**);

(±)-(*5l,1'u*)-5-(3-methyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **51**);

(±)-5-(3-methyl-3-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **52**);

(±)-5-(2-cyclopenta-1,3-dienyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **53**);

(±)-(*5l,1'l*)-5-(3-ethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **55**);

(±)-(*5l,1'u*)-5-(3-ethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **56**);

(±)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-7-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **58**);

(±)-(*5l,1'u*)-5-(3-methyl-2-cyclohexenyl)-7-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **59**);

(±)-(*5l,1'l*)-5-(3-ethyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **61**);

(±)-(*5l,1'l*)-5-(3-ethylidenecyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **62**);

(±)-(*5l,1'l*)-5-(3-methyl-3-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **63**);

(±)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-8-methoxy-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **64**);

(±)-(*5l,1'u*)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-8-methoxy-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **65**);

(±)-(*5l,1'l*)-5-(2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **67**);

(±)-(*5l,1'u*)-5-(2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **68**);

(±)-5-(1-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **69**);

(±)-(*5l,1'l*)-5-(2,3-dimethyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **71**);

(+)-(*5l,1'l*)-5-(2,3-dimethyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **73**);

(–)-(*5l,1'l*)-5-(2,3-dimethyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **74**);

(±)-(*5l,1'l*)-5-(2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **75**);

(±)-(*5l,1'u*)-5-(2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **76**);

(±)-(*5l,1'l*)-5-(2-cyclohexenyl)-7,9-difluoro-1,2,3,4-tetrahydro-2,2-dimethyl-4-methylidene-5*H*-chromeno[3,4-*f*]quinoline (compound **77**);

(±)-(*5l,1'l*)-5-(2-methylidenecyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **79**);

(±)-(*5l,1'u*)-5-(2-methylidenecyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **80**);

(±)-(*5l,1'l*)-5-(2-oxocyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **81**);

(±)-(*5l,1'u*)-5-(2-oxocyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **82**);

(±)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-9-methoxy-1,2-dihydro-1,2,2,4-tetramethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **83**);

(±)-5-(2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]-quinoline (compound **84**);

(±)-(*5l,1'l*)-5-(2,3-dimethyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **85**);

(±)-5-(3-methylidene-cyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **87**);

(±)-(*5l,1'u*)-5-(3-ethylidenecyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **88**);

(±)-*(5l,1'l)*- 5-(2-cycloheptenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (Compound **89**);

(±)-*(5l,1'l)*- 5-(2-cyclooctenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-f]quinoline (Compound **91**);

(±)-*(5l,1'u)*- 5-(2-cyclooctenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-f]quinoline (Compound **92**);

(±)-*(5l,1'l)*- 5-(2,3-epoxy-3-methylcyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (Compound **94**);

(±)-*(5l,1'l)*- 5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2,3,4-tetrahydro-2,2-dimethyl-4-methylene-5*H*-chromeno[3,4-*f*]quinolin-3-ol (Compound **95**);

(±)-*(5l,1'l)*- 5-(2,3-epoxy-2,3-dimethylcyclopentyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (Compound **96**);

(±)-*(5l,1'u)*- 5-(2,3-epoxy-3-methylcyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (Compound **97**); and

(±)-*(5l,1'l)*- 5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2,3,4-tetrahydro-2,2-dimethyl-5*H*-chromeno[3,4-*f*]quinolin-4-one (Compound **98**).

13. (Currently amended) A compound ~~according to claim 1, wherein said compound is~~ selected from the group of:

(±)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **24**);

(–)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **28**);

(–)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **33**);

(±)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **34**);

(±)-(*5l,1'u*)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **35**);

(–)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **38**);

(±)-(*5l,1'l*)-5-(3-methyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **50**);

(±)-(*5l,1'u*)-5-(3-methyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **51**);

(±)-(*5l,1'l*)-5-(2,3-dimethyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **71**);

(–)-(*5l,1'l*)-5-(2,3-dimethyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **74**); and

(±)-*(5l,1'l)*- 5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2,3,4-tetrahydro-2,2-dimethyl-5*H*-chromeno[3,4-*f*]quinolin-4-one (Compound **98**).

14. (Original) A compound of the formula:



(II)

wherein:

R^2 and R^3 each independently is selected from the group of hydrogen, C_1–C_4 alkyl, and C_1–C_4 haloalkyl;

R^6 is selected from the group of hydrogen, F, Cl, Br, CN, OR^{11}, C_1–C_4 alkyl, and C_1–C_4 haloalkyl;

R^8 and R^{10} each independently is selected from the group consisting of hydrogen, F, Cl, Br, CN, OR^{11}, $NR^{11}R^{12}$, SR^{11}, COR^{11}, C_1–C_4 alkyl, C_1–C_4 heteroalkyl, C_1–C_4 haloalkyl, allyl, and C_2–C_4 alkenyl;

R^{11} and R^{12} each is independently selected from the group of hydrogen, C_1–C_4 alkyl, C_1–C_4 heteroalkyl, and C_1–C_4 haloalkyl;

R^{14}, R^{15}, R^{18}, R^{22}, R^{23}, R^{24} each independently is selected from the group of hydrogen, F, Cl, OR^{11}, C_1–C_4 alkyl, C_1–C_4 haloalkyl, and C_1–C_4 heteroalkyl;

R^{22}, R^{23}, R^{24} together consists of not more than 3 carbon atoms;

R^{16} taken together with one of R^{14}, R^{18}, and R^{22} form a bond or "–O–" bridge;

n is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt or prodrug thereof.

15. (Original) A compound ~~according to claim 14, wherein~~ of the formula:



(II)

wherein:

R^2 and R^3 each independently is selected from the group of C_1–C_4 alkyl;

R^6 is selected from the group of F, Cl, Br, C_1–C_4 alkyl, and C_1–C_4 haloalkyl;

R^8 and R^{10} each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR^{11}, C_1–C_4 alkyl, and C_1–C_4 haloalkyl;

R^{11} and R^{12} each is independently selected from the group of hydrogen, C_1–C_4 alkyl;

R^{14}, R^{15}, R^{18}, R^{22}, R^{23}, R^{24} each independently is selected from the group of hydrogen, F, C_1–C_4 alkyl;

R^{16} taken together with one of R^{14}, R^{18}, and R^{22} form a bond or "–O–" bridge;

R^{22}, R^{23}, R^{24} together consists of not more than 3 carbon atoms; and

n is 0, 1, or 2;

or a pharmaceutically acceptable salt or prodrug thereof.

16. (Original) A compound according to claim 15, wherein

R^2 and R^3 each independently is CH_3;

R^6 is selected from the group of F, Cl, Br, CH_3, CH_2CH_3, and CF_3;

R^8 is hydrogen or F;

R^{10} is selected from the group of hydrogen, F, Cl, Br, CN, OH, OCH_3, CH_3, CH_2CH_3, and CF_3;

R^{14} and R^{16} taken together form a bond or "–O–" bridge;

R^{15}, R^{18}, R^{22}, R^{23}, and R^{24} each independently is hydrogen or CH_3.

17. (Cancelled).

18. (Currently amended) A pharmaceutical composition according to ~~claim 17~~ any one of claims 47, 48 or 49, wherein R^1 is selected from the group of hydrogen, C_1–C_4 alkyl, COR^{11}, SO_2R^{11}, and $CONR^{11}R^{12}$.

19. (Currently amended) A pharmaceutical composition according to ~~claim 17~~ any one of claims 47, 48 or 49, wherein R^2 and R^3 each independently is selected from the group of C_1–C_4 alkyl, and C_1–C_4 haloalkyl.

20. (Currently amended) A pharmaceutical composition according to ~~claim 17~~ any one of claims 47, 48 or 49, wherein

R^5 and R^7 taken together form a bond;

R^4 and R^6 each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR^{11}, C_1–C_4 alkyl, and C_1–C_4 haloalkyl.

21. (Currently amended) A pharmaceutical composition according to ~~claim 17~~ any one of claims 47, 48 or 49, wherein

R^6 and R^7 taken together are selected from the group of methylidene, and carbonyl;

R^4 and R^5 each independently is selected from the group of hydrogen, F, and C_1–C_4 alkyl.

22. (Currently amended) A pharmaceutical composition according to ~~claim 17~~ any one of claims 47, 48 or 49, wherein R^8 through R^{10} each independently is

selected from the group of hydrogen, F, Cl, Br, NO_2, CN, OR^{11}, SR^{11}, C_1–C_6 alkyl, C_1–C_6 heteroalkyl, and C_1–C_6 haloalkyl.

23. (Original) A pharmaceutical composition according to claim 22, wherein R^8 through R^{10} each independently is selected from the group of hydrogen, F, and OR^{11}.

24. (Currently amended) A pharmaceutical composition according to ~~claim 17~~ any one of claims 47, 48 or 49, wherein R^{11} through R^{12} each independently is selected from the group of hydrogen, and C_1–C_4 alkyl.

25. (Currently amended) A pharmaceutical ~~composition according to claim 17, wherein~~

composition, comprising a pharmaceutically acceptable carrier and a compound of formula:



(I)

wherein:

R^1 is selected from the group of hydrogen, C_1–C_4 alkyl, C_1–C_4 haloalkyl, C_1–C_4 heteroalkyl, COR^{11}, CO_2R^{11}, SO_2R^{11}, and $CONR^{11}R^{12}$;

R^2 and R^3 each independently is selected from the group of hydrogen, C_1–C_6 alkyl, and C_1–C_6 haloalkyl; or

R^2 and R^3 taken together form a cycloalkyl ring of from three to twelve carbons;

R^4 through R^7 each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR^{11}, C_1–C_4 alkyl, C_1–C_4 haloalkyl, and C_1–C_4 heteroalkyl; or

R^5 and R^7 taken together form a bond; or

R^6 and R^7 taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene and carbonyl;

R^8 through R^{10} each independently is selected from the group of hydrogen, F, Cl, Br, I, NO_2, CN, OR^{11}, $NR^{11}R^{12}$, SR^{11}, COR^{11}, CO_2R^{11}, $CONR^{11}R^{12}$, C_1–C_8 alkyl, C_1–C_8 heteroalkyl, C_1–C_8 haloalkyl, allyl, C_2–C_8 alkenyl and C_2–C_8 alkynyl;

R^{11} and R^{12} each is independently selected from the group of hydrogen, C_1–C_4 alkyl, C_1–C_4 heteroalkyl, and C_1–C_4 haloalkyl;

R^{13} is hydrogen;

R^{14} and R^{16} taken together form a bond or "–O–" bridge;

R^{15}, R^{17}, R^{18}, R^{19}, R^{20} each independently is selected from the group of hydrogen, F, Cl, C_1–C_4 alkyl, and C_1–C_4 haloalkyl;

R^{21} is hydrogen; or

R^{21} and R^{20} taken together form a bond; and

n is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt or prodrug thereof.

26. (Currently amended) A pharmaceutical ~~composition according to claim 17, wherein~~ composition, comprising a pharmaceutically acceptable carrier and a compound of formula:



(I)

wherein:

R^1 is selected from the group of hydrogen, C_1–C_4 alkyl, C_1–C_4 haloalkyl, C_1–C_4 heteroalkyl, COR^{11}, CO_2R^{11}, SO_2R^{11}, and $CONR^{11}R^{12}$;

R^2 and R^3 each independently is selected from the group of hydrogen, C_1–C_6 alkyl, and C_1–C_6 haloalkyl; or

R^2 and R^3 taken together form a cycloalkyl ring of from three to twelve carbons;

R^4 through R^7 each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR^{11}, C_1–C_4 alkyl, C_1–C_4 haloalkyl, and C_1–C_4 heteroalkyl; or

R^5 and R^7 taken together form a bond; or

R^6 and R^7 taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene and carbonyl;

R^8 through R^{10} each independently is selected from the group of hydrogen, F, Cl, Br, I, NO_2, CN, OR^{11}, $NR^{11}R^{12}$, SR^{11}, COR^{11}, CO_2R^{11}, $CONR^{11}R^{12}$, C_1–C_8 alkyl, C_1–C_8 heteroalkyl, C_1–C_8 haloalkyl, allyl, C_2–C_8 alkenyl and C_2–C_8 alkynyl;

R^{11} and R^{12} each is independently selected from the group of hydrogen, C_1–C_4 alkyl, C_1–C_4 heteroalkyl, and C_1–C_4 haloalkyl;

R^{13} is hydrogen;

R^{14}, R^{15}, R^{18}, R^{19}, R^{20} each independently is selected from the group of hydrogen, F, Cl, C_1–C_4 alkyl, and C_1–C_4 haloalkyl;

R^{16} and R^{17} taken together are selected from the group of methylidene, mono-substituted methylidene, and di-substituted methylidene;

R^{21} is hydrogen; or

R^{21} and R^{20} taken together form a bond; and

n is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt or prodrug thereof.

27. (Currently amended) A pharmaceutical ~~composition according to claim 17, wherein~~ composition, comprising a pharmaceutically acceptable carrier and a compound of formula:



(I)

wherein:

R^1 is selected from the group of hydrogen, C_1–C_4 alkyl, C_1–C_4 haloalkyl, C_1–C_4 heteroalkyl, COR^{11}, CO_2R^{11}, SO_2R^{11}, and $CONR^{11}R^{12}$;

R^2 and R^3 each independently is selected from the group of hydrogen, C_1–C_6 alkyl, and C_1–C_6 haloalkyl; or

R^2 and R^3 taken together form a cycloalkyl ring of from three to twelve carbons;

R^4 through R^7 each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR^{11}, C_1–C_4 alkyl, C_1–C_4 haloalkyl, and C_1–C_4 heteroalkyl; or

R^5 and R^7 taken together form a bond; or

R^6 and R^7 taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene and carbonyl;

R^8 through R^{10} each independently is selected from the group of hydrogen, F, Cl, Br, I, NO_2, CN, OR^{11}, $NR^{11}R^{12}$, SR^{11}, COR^{11}, CO_2R^{11}, $CONR^{11}R^{12}$, C_1–C_8 alkyl, C_1–C_8 heteroalkyl, C_1–C_8 haloalkyl, allyl, C_2–C_8 alkenyl and C_2–C_8 alkynyl;

R^{11} and R^{12} each is independently selected from the group of hydrogen, C_1–C_4 alkyl, C_1–C_4 heteroalkyl, and C_1–C_4 haloalkyl;

R^{13} is hydrogen;

R^{14}, R^{15}, R^{17}, R^{20} each independently is selected from the group of hydrogen, F, Cl, C_1–C_4 alkyl, and C_1–C_4 haloalkyl;

R^{16} and R^{18} taken together form a bond when n is 1; or

R^{16} and R^{19} taken together form a bond when n is 0;

R^{21} is hydrogen; and

n is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt or prodrug thereof.

28. (Currently amended) A method of treating an individual having a condition mediated by a progesterone ~~receptor~~ receptor, comprising administering to said individual a pharmaceutically effective amount of a compound according to any one of claims ~~1~~ 44, 45, 46, 12 or 14 and thereby treating said individual having a condition mediated by a progesterone receptor.

29. (Cancelled).

30. (Currently amended) A method of treating an individual having a condition mediated by a progesterone ~~receptor~~ receptor, comprising administering to said individual a pharmaceutically effective amount of a compound represented by formula (II):



(II)

wherein:

R^2 and R^3 each independently is selected from the group of hydrogen, C_1–C_4 alkyl, and C_1–C_4 haloalkyl;

R^6 is selected from the group of hydrogen, F, Cl, Br, CN, OR^{11}, C_1–C_4 alkyl, and C_1–C_4 haloalkyl;

R^8 and R^{10} each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR^{11}, $NR^{11}R^{12}$, SR^{11}, COR^{11}, C_1–C_4 alkyl, C_1–C_4 heteroalkyl, C_1–C_4 haloalkyl, allyl, and C_2–C_4 alkenyl;

R^{11} and R^{12} each is independently selected from the group of hydrogen, C_1–C_4 alkyl, C_1–C_4 heteroalkyl, and C_1–C_4 haloalkyl;

R^{14}, R^{15}, R^{18}, R^{22}, R^{23}, R^{24} each independently is selected from the group of hydrogen, F, Cl, OR^{11}, C_1–C_4 alkyl, C_1–C_4 haloalkyl, and C_1–C_4 heteroalkyl;

R^{22}, R^{23}, R^{24} together consists of not more than 3 carbon atoms;

R^{16} taken together with one of R^{14}, R^{18}, and R^{22} form a bond or "–O–" bridge;

n is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt or prodrug thereof;

and thereby treating said individual having a condition mediated by a progesterone receptor.

31. (Original) A method according to claim 28, wherein said condition is selected from the group of dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flushes, mood disorders, meningiomas, hormone-dependent cancers and female osteoporosis.

32. (Original) A method according to claim 28, wherein said condition is alleviated with female hormone replacement therapy.

33. (Currently amended) A method of modulating fertility in an ~~individual~~ individual, comprising administering to said individual a pharmaceutically effective amount of a compound according to any one of claims ~~1~~ 44, 45, 46, 12 or 14 and thereby modulating fertility in said individual.

34. (Currently amended) A method of providing contraception to an ~~individual~~ individual, comprising administering to said individual a pharmaceutically effective amount of a compound according to any one of claims ~~1~~ 44, 45, 46, 12 or 14 and thereby providing contraception to said individual.

35. (Currently amended) A method of modulating a progesterone receptor in an ~~individual~~ individual, comprising administering to said individual a compound according to any one of claims ~~1~~ 44, 45, 46, 12, or 14 in an amount effective to modulate a progesterone receptor and thereby modulating a progesterone receptor in said individual.

36. (Original) A method according to claim 35, wherein said modulation is activation.

37. (Original) A method according to claim 36, wherein said compound provides at least 50% maximal activation of the progesterone receptor at a concentration of less than 100 nM.

38. (Original) A method according to claim 36, wherein said compound provides at least 50% maximal activation of the progesterone receptor at a concentration of less than 50 nM.

39. (Original) A method according to claim 36, wherein said compound provides at least 50% maximal activation of the progesterone receptor at a concentration of less than 20 nM.

40. (Original) A method according to claim 36, wherein said compound provides at least 50% maximal activation of the progesterone receptor at a concentration of less than 10 nM.

41. (Currently amended) A method of treating hormone-dependent cancer, comprising administering to a patient in need thereof an effective amount of a compound according to any one of claims ~~1~~ 44, 45, 46, 12 or 14.

42. (Original) A method according to claim 41, wherein said cancer is selected from the group of ovarian cancer, breast cancer, endometrium cancer and prostate cancer.

43. (Currently amended) A method of determining the presence of a progesterone receptor (PR) in a cell or cell ~~extract~~ extract, comprising:

(a) labeling a compound ~~according to~~ of any one of claims ~~1~~ 44, 45, 46, 12 or 14;

(b) contacting the cell or cell extract with ~~said~~ the labeled compound; and

(c) testing the ~~contracted~~ contacted cell or cell extract to ~~determine the presence of progesterone receptor~~ detect label and thereby determining the presence of a progesterone receptor (PR) in the cell or cell extract.

44. (New) A compound of the formula:



(I)

wherein:

R^1 is selected from the group of hydrogen, C_1–C_4 alkyl, C_1–C_4 haloalkyl, C_1–C_4 heteroalkyl, COR^{11}, CO_2R^{11}, SO_2R^{11}, and $CONR^{11}R^{12}$;

R^2 and R^3 each independently is selected from the group of hydrogen, C_1–C_6 alkyl, and C_1–C_6 haloalkyl; or

R^2 and R^3 taken together form a cycloalkyl ring of from three to twelve carbons;

R^4 through R^7 each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR^{11}, C_1–C_4 alkyl, C_1–C_4 haloalkyl, and C_1–C_4 heteroalkyl; or

R^5 and R^7 taken together form a bond; or

R^6 and R^7 taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene and carbonyl;

R^8 through R^{10} each independently is selected from the group of hydrogen, F, Cl, Br, I, NO_2, CN, OR^{11}, $NR^{11}R^{12}$, SR^{11}, COR^{11}, CO_2R^{11}, $CONR^{11}R^{12}$, C_1–C_8 alkyl, C_1–C_8 heteroalkyl, C_1–C_8 haloalkyl, allyl, C_2–C_8 alkenyl and C_2–C_8 alkynyl;

R^{11} and R^{12} each is independently selected from the group of hydrogen, C_1–C_4 alkyl, C_1–C_4 heteroalkyl, and C_1–C_4 haloalkyl;

R^{13} is hydrogen;

R^{14} through R^{20} each independently is selected from the group of hydrogen, F, Cl, Br, OR^{11}, C_1–C_4 alkyl, C_1–C_4 haloalkyl, and C_1–C_4 heteroalkyl; or

R^{14} and R^{15} taken together are selected from the group of methylidene, carbonyl and thiocarbonyl; or

R^{16} and R^{17} taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene, carbonyl and thiocarbonyl; or

R^{14} and R^{16} taken together form a bond or "–O–" bridge; or

R^{16} and R^{18} taken together form a bond when n is 1; or

R^{16} and R^{19} taken together form a bond when n is 0;

R^{21} is hydrogen; or

R^{21} and R^{20} taken together form a bond;

n is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt or prodrug thereof.

45. (New) A compound of the formula:



(I)

wherein:

R^1 is selected from the group of hydrogen, C_1–C_4 alkyl, C_1–C_4 haloalkyl, C_1–C_4 heteroalkyl, COR^{11}, CO_2R^{11}, SO_2R^{11}, and $CONR^{11}R^{12}$;

R^2 and R^3 each independently is selected from the group of hydrogen, C_1–C_6 alkyl, and C_1–C_6 haloalkyl; or

R^2 and R^3 taken together form a cycloalkyl ring of from three to twelve carbons;

R^4 through R^7 each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR^{11}, C_1–C_4 alkyl, C_1–C_4 haloalkyl, and C_1–C_4 heteroalkyl; or

R^5 and R^7 taken together form a bond; or

R^6 and R^7 taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene and carbonyl;

R^8 through R^{10} each independently is selected from the group of hydrogen, F, Cl, Br, I, NO_2, CN, OR^{11}, $NR^{11}R^{12}$, SR^{11}, COR^{11}, CO_2R^{11}, $CONR^{11}R^{12}$, C_1–C_8 alkyl, C_1–C_8 heteroalkyl, C_1–C_8 haloalkyl, allyl, C_2–C_8 alkenyl and C_2–C_8 alkynyl;

R^{11} and R^{12} each is independently selected from the group of hydrogen, C_1–C_4 alkyl, C_1–C_4 heteroalkyl, and C_1–C_4 haloalkyl;

R^{13} is hydrogen; or

R^{13} and R^{14} taken together form a bond;

R^{14} through R^{20} each independently is selected from the group of hydrogen, F, Cl, Br, OR^{11}, C_1–C_4 alkyl, C_1–C_4 haloalkyl, and C_1–C_4 heteroalkyl; or

R^{14} and R^{15} taken together are selected from the group of methylidene, carbonyl and thiocarbonyl; or

R^{16} and R^{17} taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene, carbonyl and thiocarbonyl; or

R^{14} and R^{16} taken together form a bond or "–O–" bridge;

R^{16} and R^{19} taken together form a bond when n is 0;

R^{21} is hydrogen; or

R^{21} and R^{20} taken together form a bond;

n is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt or prodrug thereof.

46. (New) A compound of the formula:



(I)

wherein:

R^1 is selected from the group of hydrogen, C_1–C_4 alkyl, C_1–C_4 haloalkyl, C_1–C_4 heteroalkyl, COR^{11}, CO_2R^{11}, SO_2R^{11}, and $CONR^{11}R^{12}$;

R^2 and R^3 each independently is selected from the group of hydrogen, C_1–C_6 alkyl, and C_1–C_6 haloalkyl; or

R^2 and R^3 taken together form a cycloalkyl ring of from three to twelve carbons;

R^4 through R^7 each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR^{11}, C_1–C_4 alkyl, C_1–C_4 haloalkyl, and C_1–C_4 heteroalkyl; or

R^5 and R^7 taken together form a bond; or

R^6 and R^7 taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene and carbonyl;

R^8 through R^{10} each independently is selected from the group of hydrogen, F, Cl, Br, I, NO_2, CN, OR^{11}, $NR^{11}R^{12}$, SR^{11}, COR^{11}, CO_2R^{11}, $CONR^{11}R^{12}$, C_1–C_8 alkyl, C_1–C_8 heteroalkyl, C_1–C_8 haloalkyl, allyl, C_2–C_8 alkenyl and C_2–C_8 alkynyl;

R^{11} and R^{12} each is independently selected from the group of hydrogen, C_1–C_4 alkyl, C_1–C_4 heteroalkyl, and C_1–C_4 haloalkyl;

R^{13} is hydrogen; or

R^{13} and R^{14} taken together form a bond;

R^{14} through R^{20} each independently is selected from the group of hydrogen, F, Cl, Br, OR^{11}, C_1–C_4 alkyl, C_1–C_4 haloalkyl, and C_1–C_4 heteroalkyl; or

R^{14} and R^{15} taken together are selected from the group of methylidene, carbonyl and thiocarbonyl; or

R^{16} and R^{17} taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene, carbonyl and thiocarbonyl; or

R^{14} and R^{16} taken together form a bond or "–O–" bridge; or

R^{16} and R^{18} taken together form a bond when n is 1; or

R^{16} and R^{19} taken together form a bond when n is 0;

R^{21} is hydrogen;

n is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt or prodrug thereof.

47. (New) A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a compound of any one of claims 44-46.